Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

A Clinical Trial to Evaluate the Effects of Two Supplements on Cognitive Function, Cognitive Performance, and Mood

11 augustus 2026 bijgewerkt door: BrainJuice

This study evaluates the effects of two liquid dietary supplements, BrainJuice Peach Mango (test product one) and BrainJuice ACTIVE Pomegranate Acai (test product two), on cognitive function, cognitive performance, and mood in healthy adults aged 18-57 who report concerns in these areas. The trial is a six-week, single-arm, open-label, virtual study enrolling 30 participants.

Participants will consume test product one (2.5 oz once daily) during Weeks 1 and 2, undergo a washout period during Weeks 3 and 4, and then consume test product two (2.5 oz once daily) during Weeks 5 and 6. Cognitive function will be assessed via standardized computerized cognitive assessments at Baseline, Week 2, Week 4, and Week 6, while perceptions of cognitive function, cognitive performance, and mood will be captured through self-reported questionnaires at Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Werkelijk)

30

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Volwassen

Accepteert gezonde vrijwilligers

Ja

Beschrijving

Inclusion Criteria:

  • Be male or female
  • Be aged 18-57
  • Anyone experiencing concerns regarding all of the following over the past four weeks: Cognitive Function, Cognitive Performance, and Mood
  • Anyone who is generally healthy - does not live with any uncontrolled chronic disease
  • If taking oral over-the-counter supplements or herbal remedies targeted at cognitive function, cognitive performance, or mood, has been consistently taking these for at least 3 months prior to starting the study, and is willing to maintain this routine for the study duration
  • Anyone who is a regular caffeine consumer without a history of caffeine sensitivity or intolerance
  • Willing to maintain the same diet and exercise regimen consistently throughout the study duration
  • Willing to limit caffeine consumption to one additional serving of caffeine outside of the test product i.e. one cup of brewed coffee (~100 mg), one matcha (~60 mg), two shots of espresso (~120 mg), or one cup of caffeinated tea (~50 mg)
  • Resides in the United States
  • Has access to a computer or tablet device

Exclusion Criteria:

  • Anyone with pre-existing chronic conditions, including but not limited to oncological, uncontrolled hypertension (high blood pressure) or hypotension (low blood pressure), heart disease, diabetes and psychiatric disorders
  • History of neurodegenerative disease (e.g., Alzheimer's, Parkinson's), history of traumatic brain injury (including concussions), stroke, epilepsy, or uncontrolled migraine
  • History of mood disorders, such as depression, bipolar disorder, or seasonal affective disorder
  • History of sleep disorders, such as insomnia, narcolepsy, or sleep apnea
  • Anyone with a job that involves shift work that may be overnight or night hours
  • Planning on introducing any products or any new forms of prescription medication or supplements that target cognitive function, cognitive performance, or mood, for the study duration
  • Anyone with any allergies or sensitivities to any of the study product ingredients
  • Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period)
  • Anyone unwilling to follow the study protocol
  • Anyone with a history of substance abuse
  • Anyone who is currently a smoker or has been a smoker in the past 3 months
  • Currently partaking in another research study or will be partaking in any other research study at any point during this study's duration

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Ander
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: BrainJuice Supplement
All participants consume BrainJuice Peach Mango (test product one, 2.5 oz once daily) during Weeks 1 and 2, followed by a washout period during Weeks 3 and 4 with no test product, followed by BrainJuice ACTIVE Pomegranate Acai (test product two, 2.5 oz once daily) during Weeks 5 and 6. There is no comparator or placebo arm.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in Cognitive Assessment Score (Polygons)
Tijdsspanne: Baseline, Week 2, Week 4, and Week 6
Mean change in Polygons processing test score from Baseline, measured via computerized cognitive assessment
Baseline, Week 2, Week 4, and Week 6
Change in Cognitive Assessment Score (Double Trouble)
Tijdsspanne: Baseline, Week 2, Week 4, and Week 6
Mean change in Double Trouble selective attention and processing speed test score from Baseline, measured via computerized cognitive assessment
Baseline, Week 2, Week 4, and Week 6
Change in Cognitive Assessment Score (Feature Match)
Tijdsspanne: Baseline, Week 2, Week 4, and Week 6
Mean change in Feature Match focus and processing test score from Baseline, measured via computerized cognitive assessment
Baseline, Week 2, Week 4, and Week 6
Change in Cognitive Assessment Score (Paired Associates)
Tijdsspanne: Baseline, Week 2, Week 4, and Week 6
Mean change in Paired Associates memory task score from Baseline, measured via computerized cognitive assessment
Baseline, Week 2, Week 4, and Week 6
Change in Cognitive Assessment Score (Digit Span)
Tijdsspanne: Baseline, Week 2, Week 4, and Week 6
Mean change in Digit Span short-term memory and attention test score from Baseline, measured via computerized cognitive assessment
Baseline, Week 2, Week 4, and Week 6
Change in Cognitive Assessment Score (Spatial Planning)
Tijdsspanne: Baseline, Week 2, Week 4, and Week 6
Mean change in Spatial Planning executive function test score from Baseline, measured via computerized cognitive assessment
Baseline, Week 2, Week 4, and Week 6

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change in Self-Reported Focus
Tijdsspanne: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Mean change in perceived focus from Baseline, assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Attention
Tijdsspanne: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Mean change in perceived attention from Baseline, assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Concentration
Tijdsspanne: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Mean change in perceived concentration from Baseline, assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Productivity
Tijdsspanne: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Mean change in perceived productivity from Baseline, assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Alertness
Tijdsspanne: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Mean change in perceived alertness from Baseline, assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Mental Clarity
Tijdsspanne: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Mean change in perceived mental clarity from Baseline, assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Mood
Tijdsspanne: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Mean change in perceived mood from Baseline, assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Mental Fatigue
Tijdsspanne: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Mean change in perceived mental fatigue from Baseline, assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Motivation
Tijdsspanne: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Mean change in perceived motivation from Baseline, assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Change in Self-Reported Organization
Tijdsspanne: Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6
Mean change in perceived organization from Baseline, assessed via self-reported questionnaire
Baseline, Week 1, Week 2, Week 4, Week 5, and Week 6

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Medewerkers

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

9 november 2025

Primaire voltooiing (Werkelijk)

6 februari 2026

Studie voltooiing (Werkelijk)

6 februari 2026

Studieregistratiedata

Eerst ingediend

11 augustus 2026

Eerst ingediend dat voldeed aan de QC-criteria

11 augustus 2026

Eerst geplaatst (Werkelijk)

14 augustus 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

14 augustus 2026

Laatste update ingediend die voldeed aan QC-criteria

11 augustus 2026

Laatst geverifieerd

1 augustus 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • 20807 (Andere identificatie: Fred Hutch/University of Washington Cancer Consortium)
  • legacy-20807

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren